Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction

Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) in patients with type 2 diabetes reduces the risk of serious heart failure events, specifically the risk of hospitalization for heart failure, and cardiovascular death. The benefit is most apparent in patients with a heart failure with reduced ejecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhamid, Magdy, Kandil, Hossam, Hassanin, Mahmoud, Shaheen, Sameh, Sobhy, Mohamed, ElEtreby, Adel, Hasan‐Ali, Hosam, Mahfouz, Hala, Nasr, Gamila, Shawky, Islam, Emil, Sameh, ElSetiha, Mohamed, Hasssan, Mohamed, Sadek, Yasser, Karim, Mohamed Abdelghany, Asham, Ayman, Ghaleb, Mohamed, Samir, Ahmad, Shokry, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934981/
https://www.ncbi.nlm.nih.gov/pubmed/35118822
http://dx.doi.org/10.1002/ehf2.13811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934981/
https://www.ncbi.nlm.nih.gov/pubmed/35118822
http://dx.doi.org/10.1002/ehf2.13811

Ejemplares similares